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Background: In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts
recurrence-free survival but is invasive and prone to sampling error. [18F]Fluorodeoxyglucose (FDG) positron
emission tomography (PET) has shown an early agonist or ‘flare’ response to tamoxifen and estradiol, but has
not been tested in response to estrogen-lowering aromatase inhibitors (AIs). We hypothesized that decreased
agonistic response to AIs would result in early FDG uptake decline. We also measured early response to
trastuzumab (T), another targeted agent for breast cancer with differing mechanisms of action. Our study was
designed to test for an early decline in FDG uptake in response to AI or T and to examine association with Ki-67
measures of early response.
Methods: Patients with any stage of newly diagnosed or recurrent breast cancer were eligible and enrolled prior
to initiation (or resumption) of AI or T therapy. FDG PET and tissue biopsy were planned before and after 2
weeks of AI or T therapy, with pretreatment archival tissue permitted. Cutoffs of ≥20% decline in standardized
uptake value (SUV) as FDG PET early response and ≤5% post-treatment expression as Ki-67 early response were
defined prior to analysis.
Results: Forty-two patients enrolled, and 40 (28 AI, 12 T) completed serial FDG-PET imaging. Twenty-two patients
(17 AI, 5 T) had newly diagnosed disease, and 23 (14 AI, 9 T) had metastatic disease (5 newly diagnosed).
Post-treatment biopsy was performed in 25 patients (63%) and was either refused or not feasible in 15.
Post-treatment biopsy yielded tumor in only 17/25 cases (14 AI, 3 T). Eleven of 14 AI patients with post-therapy
tissue showed FDG PET early response, and there was 100% concordance of PET and post-therapy Ki-67 early
response. For the T group, 6/12 showed an FDG PET early response, including 2/3 patients with post-therapy
biopsy, all with Ki-67 >5%.
Conclusions: Substantial changes in FDG PET SUV occurred over 2 weeks of AI therapy and were associated
with low post-therapy proliferation. SUV decline was seen in response to T, but few tissue samples were
available to test association with Ki-67. Our results support further investigation of FDG PET as a biomarker for
early response to AI therapy.
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Breast cancer is a common, life-threatening malignancy
[1]; its biology may be driven by estrogen receptor (ER)
expression and/or by overexpression or amplification of
the epidermal growth factor family receptor HER2.
Endocrine therapies such as aromatase inhibitors (AI)
and targeted monoclonal antibodies such as trastuzumab
(T; HerceptinW, Genentech, South San Francisco, CA,
USA) have dramatically improved breast cancer out-
comes for patients with tumors bearing the appropriate
marker for response: ER for AIs and HER2 for T. How-
ever, not all tumors bearing these receptors respond to
targeted therapy. Furthermore, in the metastatic setting,
initial response to targeted therapy is commonly fol-
lowed by eventual disease progression and resistance to
therapy. Additional predictive markers of treatment sen-
sitivity and resistance could allow rapid identification of
effective treatments and avoidance of futile therapy.
Ki-67, an immunohistochemical assay of tumor prolif-
eration [2], has been demonstrated to be a biomarker of
early response to chemotherapy [3] and endocrine therapy
[4,5]. In a study of 158 patients undergoing endocrine
therapy (anastrozole or tamoxifen or anastrozole + tamoxi-
fen), higher Ki-67 after 2 weeks of therapy predicted
shorter recurrence-free survival, with a hazard ratio of
1.95 (95% CI 1.23 to 3.07) for 2.7-fold higher Ki-67, con-
trolling for the effects of tumor size and quantitative ER
level [4]. Data regarding the predictive utility of Ki-67 and
other markers for HER2-targeted therapy are more lim-
ited. In vitro studies have suggested that the HER2-
targeting tyrosine kinase inhibitor lapatinib has direct
effects on pathways involving proliferation [6], supporting
Ki-67 as a candidate biomarker for early response to
HER2-targeted therapy. However, other evidence suggests
that the primary mechanism of the HER2-targeted mono-
clonal antibody trastuzumab is pro-apoptotic [6-8]. Fur-
ther study is needed to understand the mechanisms of
HER2-targeted therapy and to identify markers of early
response [9].
Although the evidence is strong for Ki-67 as an early
response biomarker for endocrine therapy, serial tissue
biopsies are not always practical, and not all biopsies
yield evaluable tumor tissue. Noninvasive imaging tech-
niques which evaluate the entire tumor burden can
overcome these obstacles and offer serial evaluation of
tumor metabolic activity in vivo. 2-Deoxy-2-[18F]fluoro-
D-glucose positron emission tomography (FDG PET)
holds promise as a marker of tumor glycolysis that may
parallel Ki-67 [10,11] as an indirect measure of cell pro-
liferation [12]. Serial FDG PET can serve as a pharma-
codynamic marker of response to chemotherapy in
several tumors, including breast [13-15]. FDG PET is
widely available and has been shown to predict re-
sponse to breast cancer-targeted therapy as well aschemotherapy. For example, an agonist response to
endocrine therapy or introduction of estradiol results in
a ‘metabolic flare’ of FDG uptake that predicts clinical
response to endocrine therapy [16-18]. FDG PET may
also show an early response to the HER2-targeted agent
lapatinib [14]. Based upon these data, we hypothesized
that reductions in estrogen levels induced by AI therapy
would result in an early decline in FDG PET standar-
dized uptake value (SUV). This pilot study also
explored whether a similar response would be seen in
HER2-targeted therapy with T.
To determine whether change in FDG PET SUV at 2
weeks into therapy concurs with the 2-week proliferative
index (Ki-67), we paired imaging and tissue assays in
two groups: patients with ER+ disease initiating AI ther-
apy and patients with HER2+ disease initiating T ther-
apy. We hypothesized that change in FDG SUV would
parallel post-therapy Ki-67.
Methods
Study design and patient population
Patients were screened and recruited from the breast
oncology clinic at the University of Washington
housed at the Seattle Cancer Care Alliance. Eligibility
was broad, encompassing patients with de novo or re-
current disease planning therapy containing AI or T.
No restrictions were placed on tumor stage, endocrine
therapy history, or chemotherapy history. Washout
periods for prior therapy were observed as clinically
indicated. Inclusion criteria included biopsy-proven
breast cancer with confirmation of ER or HER2 ex-
pression and lesions large enough (>3 cm diameter)
to avoid FDG PET partial volume effects. Our primary
endpoints were early response by FDG PET and tissue
assay, rather than response by RECIST criteria [19],
so patients with bone-dominant metastatic breast can-
cer were eligible if bone lesions were approximately
3 cm or larger and detected by FDG PET. Premenopau-
sal patients could enroll in the AI arm if ovarian sup-
pression was also administered, starting at least
2 weeks prior to AI. Patients with tumors which were
both ER+ and HER2+ were eligible for either arm,
but single-agent therapy for the 2-week study period
was required.
Patients underwent a pretreatment biopsy or con-
sented to make a tissue block available from an earlier
biopsy. A biopsy was performed after 2 weeks of therapy
when feasible. FDG PET was performed pretreatment
and after 2 weeks of therapy. After this 2-week brief
therapeutic exposure (‘run-in’) test of single-agent ther-
apy, patients then continued the single agent or added
cytotoxic chemotherapy as planned. Neither study im-
aging nor 2-week study biopsy results were used to dir-
ect further treatment. Clinical response at 6 months was
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report, but was not part of this analysis. Participants
gave written informed consent, and the study was
approved by the University of Washington Institutional
Review Board.
Tissue specimens and Ki-67
Baseline tissue was obtained as clinically indicated, from
a diagnostic biopsy or remote biopsy of metastatic tissue.
The 2-week study biopsy was taken from the breast
when tumor was present, but permitted to be sampled
from the skin, nodes, bone, or other sites as clinically
indicated. Biopsy of multiple sites was not considered,
out of concern for patient comfort. Nonconcurrent
‘baseline’ tumor blocks were not requested for patients
who did not have follow-up biopsy results.
Paraffin-embedded blocks were analyzed at the Uni-
versity of Washington Pathology Laboratory for Ki-67
using a working dilution of 1:500 of MIB-1 antibody
from DakoCytomation (Carpenteria, CA, USA). Al-
though consensus guidelines had not been published at
the time of analysis [2], Ki-67 assay followed the consen-
sus protocol, with the exception of estimating the prolif-
eration index from counts of 500 cells. Ki-67 was scored
as the percentage of positively staining cells, based on
counts of approximately 50 cells compared to standar-
dized images and verified by a single observer blinded to
the PET results. The Ki-67 assay is standard at our insti-
tution, and results were documented in the patients'
medical record. However, the assays were performed in
batches so post-therapy results were not routinely avail-
able to clinicians within a timeframe that could influence
treatment. Status for other breast cancer markers (ER,
PgR, HER2) was ascertained from the medical record,
from the most recent assessment.
A post-therapy Ki-67 index of ≤5% was considered to
confer a favorable prognosis. On a continuous scale for
logged values, higher Ki-67 after 2 weeks of endocrine
therapy has been found to be associated with shorter
recurrence-free survival [4]. Cut points are desirable for
eventual personalized therapy decisions, but are not yet
standard due to differences in assay implementation and
lack of data for cut point validation [2]. We chose a cut
point of ≤5% as the lower limit of detection for our assay
and a marker of cell cycle response [20].
Imaging
FDG PET was performed on an ADVANCE PET scanner
or a Discovery STE PET/CT scanner (GE Medical Sys-
tems, Waukesha, WI, USA), both in routine use at our
center. Some patients' follow-up studies were performed
on a different PET or PET/CT scanner, when the pre-
therapy scanner was not available. However, scanners
were regularly cross-calibrated using quantitativeimaging phantom measurements. Patients underwent
FDG PET or PET/CT using 7 to 10 mCi of FDG, infused
over 1 min. Patient preparation instructions followed
consensus guidelines [21], including fasting for 6+ h,
maintaining hydration, and avoiding vigorous exercise
for 24 h prior to scanning. Plasma glucose was measured
prior to scanning, and the scan was not performed if
glucose was >200 mg/dL. Imaging began 60 min after
injection and consisted of five adjacent imaging fields
covering neck to pelvis, with 7-min emission collections
per field. Attenuation correction was performed from
segmentation of transmission images (3 min per field,
ADVANCE) or CT images (Discovery STE). Images were
reconstructed using filtered backprojection with a
smoothing filter, resulting in approximately 10-mm full
width at half maximum resolution.
Images were analyzed prospectively by a single obser-
ver (DAM), with correlative anatomic imaging (typically
CT) for assistance with tumor identification. If multiple
lesions were present, a single index lesion for both FDG
PET scans was chosen with the highest FDG uptake at
baseline. When possible, a lesion amenable to post-
therapy biopsy was chosen as the index lesion. The
percent change in index lesion maximum FDG SUV
compared to baseline was the primary analysis parameter
for evaluating early response. An SUV decline of ≥20%,
twice an accepted 10% test-retest reproducibility stand-
ard deviation [22], was considered to be attributable to
treatment. This is a smaller threshold than the ≥30% and
≥0.8 unit decrease required for partial response under
the PET Response Criteria in Solid Tumors (PERCIST)
version 1.0 [23], but is justified by the short timeframe of
treatment and the acceptance of lower thresholds in
other consensus criteria [24].
Statistical analysis
The nonparametric Wilcoxon rank sum test was used to
compare distributions of AI and T groups for continuous
measures such as SUV, Ki-67, and percent change in
SUV. Spearman rank correlations were used to
summarize associations between tissue and imaging
measures. Other analyses of these pilot data were de-
scriptive. The study was designed to test the ability of
FDG PET to detect early response to AI or T (≥20%
SUV decline) in 40% of patients, an approximate rate of
clinical response to these targeted therapies. Assuming a
sample size of 20 for each treatment group and 15 per-
centage point standard deviation for SUV decline, the
power to observe FDG PET early response in at least
8/20 patients was 0.65 if the study population included
40% treatment responders. If 60% of the study popula-
tion were responders to targeted therapy, the probability
of observing FDG PET early response in 8+ of 20 patients
was 0.97. Analyses were conducted using R version 2.13.1









Age, years 58 (35, 83) 48 (38, 71)
Postmenopausal 21 (75%) 9 (75%)
ER positive 28 (100%) 6 (50%)
PgR positive 26 (93%) 6 (50%)
HER2
Negative 25 (89%) 0 (0%)
Positive 0 (0%) 12 (100%)
Equivocal/not done 3 (11%) 0 (0%)
Disease status
Newly diagnosed 17 (61%) 5 (42%)
Recurrent 11(39%) 7 (58%)
Disease stage
Stage I-III (newly diagnosed) 14 (50%) 3 (25%)
Metastatic (newly diagnosed) 3 (11%) 2 (17%)
Metastatic (recurrent,
newly stage IV)
5 (18%) 5 (41%)
Metastatic (recurrent
stage IV)
6 (21%) 2 (17%)
Histology
Ductal 14 (50%) 9 (75%)
Lobular 9 (32%) 1 (8%)
Ductal and lobular 2 (7%) 0 (0%)
Unknown 3 (11%) 2 (17%)
PET index lesion
Breast 16 (57%) 5 (41%)
Nodal/soft tissue 6 (21%) 3 (25%)
Bone 1 (4%) 2 (17%)
Visceral 5 (18%) 2 (17%)
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Forty-two patients were enrolled to the study, but one
withdrew consent before the first PET scan and another,
before the second PET scan. Thus, the analysis sample
was 40 patients (28 undergoing an AI run-in, 12 under-
going T run-in). All 6 patients who enrolled with dual
positive tumors (ER+ and HER2+) opted for HER2-
targeted therapy. One patient did not comply with AI
therapy during the run-in period, leaving 39 early
response-evaluable patients enrolled between December
2006 and October 2009. Table 1 describes patient char-
acteristics for the AI and T cohorts. Seventeen AI-
treated patients had de novo disease: 3 presented with
metastatic disease, and 14 presented with stage I-III dis-
ease (nine of these patients were co-enrolled in a clinical
trial of neoadjuvant therapy, NCT00194792, in which
the AI run-in was followed by neoadjuvant chemother-
apy +AI). The remaining 11 AI patients had recurrent
stage IV disease up to 29 years after primary therapy. Six
of these 11 AI patients had a history of endocrine ther-
apy (tamoxifen, fulvestrant), including four with prior AI
exposure. Five T-treated patients had de novo disease
(two with metastatic disease at diagnosis). Five had re-
current disease newly diagnosed as stage IV, and two
had recurrent metastatic disease. Four of the seven T-
treated patients with recurrent disease had prior adju-
vant T exposure, including one who had also received T
for metastatic disease.
FDG PET
Imaging findings are summarized in Table 2 and Fig-
ure 1. Baseline SUV had a similar range for AI (median
4.6, range 1.6 to 18.9) and T groups (median 8.9, range
2.6 to 17.2), but on average, values were somewhat lower
for the AI group (W= 93, p= 0.03), as would be expected
for ER-expressing tumors [25]. The median number of
days between FDG PET scans was 18 days for the AI
group and 15 days for the T group and ranged from 12
to 33 days. The maximum glucose level measured was
138 mg/dL, and for 39 patients with plasma glucose
recorded at both scans, the median absolute difference
between scans was 10 mg/dL (range 0 to 50 mg/dL).
Time between FDG injection and scanning was available
for 78 scans and was performed 55 to 65 min after injec-
tion for 58 (74%), with another 12 performed at about
45 min and 8 at 66 to 85 min after injection. Timing for
the two scans differed by more than 20 min for three
patients in the AI group, but in each case, scan timing
would not have influenced early response classification(for example, one patient had a baseline SUV of 4.4 at
67.5 min and a post-therapy SUV of 3.8 at 45 min after
injection. Any adjustment based on uptake time would
attenuate the 14% decline toward 0%).
FDG SUV declined in most patients on targeted ther-
apy. Figure 1 shows a spaghetti plot of individual
patients' FDG SUV for baseline and post-therapy for AI
(Figure 1a) and T-treated (Figure 1b) groups undergoing
approximately 2 weeks of targeted therapy. No patients
showed increases in SUV greater than 11%, but 74% of
AI patients (20/27) and 50% of T patients (6/12) had
decreases in SUV of 20% to 75%. The noncompliant AI
patient (pink line), who did not undertake any treatment
between scans, had a baseline SUV of 2.3 and a follow-
up SUV of 2.4. The distribution of percent change in
SUV did not differ for the AI and T treatment groups









SUVmax of index lesion
at baseline
28 4.6 (1.6, 18.9) 12 8.9 (2.6, 17.2)
Days between FDG PET scans 28 18 (12, 33) 12 15 (13, 29)
SUVmax of index lesion
at follow-up
28 3.2 (1.2, 13.6) 12 5.3 (1.6, 17.1)
Percent change in SUVmax 28 −28 (−60, 11) 12 −25 (−75, 9)
Patients with FDG PET
early response
(≥20% SUV decline)
20 (71%) 6 (50%)
Ki-67 prior to run-in
therapy (%)
22 15 (<5, 41) 5 40 (5, 60)
Days between
successful biopsies
14 51 (16, 608) 3 29 (14, 49)
Ki-67 following
run-in therapy (%)
14 5 (0.5, 60) 3 25 (20, 60)
Patients with Ki-67 ≤5%
following run-in therapy
11 (79%) 0 (0%)
Change in Ki-67 14 −8 (−26, 30) 3 0 (−15, 15)
Figure 1 Baseline and follow-up measures. (a) AI therapy, FDG PET SUV
therapy, Ki-67% staining.
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early response (≥20% decline) and non-response are
shown in Figure 2.Ki-67
For all newly diagnosed patients (17 AI, 5 T), baseline
biopsies were obtained within 3 months of the first FDG
PET scan. For the remaining 11 AI patients, five baseline
biopsies had been performed within 3 months, and the
remaining 6 were archival. For the remaining seven T
patients, five had undergone recent biopsies, and 2 sam-
ples were archival (5+ years old). Of these baseline biop-
sies, 13 (6 AI, 7 T) were not assessed for Ki-67 because
the archival tissue could not readily be obtained, and
follow-up Ki-67 was not acquired. Twenty-seven of 40
biopsies (68%) were of breast tissue. The remainder
included the nodes (n= 3), liver (n= 3), and bone (n= 3).
Baseline Ki-67 was >5% for 17/22 patients in the AI
group (77%) and for 4/5 (80%) in the T group.
Figure 3 demonstrates the compliance and yield of bi-
opsy following a 2-week therapy run-in period. Biopsy




Figure 2 Early FDG PET response examples. (a) Trans-axial FDG PET views show left breast lesion with baseline SUV of 4.6 and follow-up SUV
of 2.5 (46% decrease). Clinical response was observed after 4 months of neoadjuvant therapy +AI. (b) Coronal FDG PET views show left axillary
lymph node with baseline SUV of 4.5 and follow-up SUV of 4.5 (0% change). This patient experienced progressive disease after 7 months of AI
monotherapy.
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opsies performed, 8 (32%) failed to yield sufficient tumor
tissue to assess Ki-67 (5 breast biopsies, 2 bone marrow/
iliac crest, 1 axillary lymph node). The 17 successful 2-
week biopsies (14 AI, 3 T) were all repeated samples
from the baseline biopsy location, 16 from breast tissue
and 1 from an axillary lymph node. Figure 1c (AI) and
Figure 1d (T) show Ki-67 decline in the majority of
patients on AI therapy. Following run-in, 11/14 of the
AI group (79%) and 0/3 of the T group had K-67 ≤5%.
Correlation of FDG PET and Ki-67 results
We examined the correlation between change in SUV by
FDG PET and tissue assay of Ki-67 by testing associa-
tions between baseline, 2-week absolute values, and per-
centage change. As shown in Figure 4a and discussed
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Figure 3 Flow chart for 40 study participants completing serial
FDG PET.most patients who were candidates for T therapy (red
points) than for candidates for AI therapy. Otherwise,
there was not a clear association between baseline levels
for Ki-67 and FDG SUV (AI sample, Spearman rho =
−0.07, p= 0.74). As shown in Figure 4b, change in Ki-67
and percent change in FDG SUV were also not strongly
associated (AI sample, Spearman rho = 0.23, p= 0.44).
However, the expected association between follow-up
Ki-67 and percent change in FDG SUV was quite robust
for the AI group (Figure 4c, AI sample Spearman rho =
0.77, p= 0.001). For all 11 patients in the AI group who
showed an SUV decline of 20% or greater, the Ki-67 at
follow-up was ≤5%; for all three AI patients who did not
attain SUV reductions of 20% or greater, the Ki-67 at
follow-up was >5%. The T group (red points) was too
small to draw conclusions, but did not appear to show
this pattern: two of three patients with serial biopsy had
substantial reductions in FDG SUV (38% and 57%), but
follow-up Ki-67 was >5% (20% and 25%).
Discussion
FDG SUV demonstrated substantial decline over a 2-
week course of AI therapy. This is consistent with the
reasoning that if hormone-dependent breast cancers re-
spond to estradiol challenge with an increase in FDG
uptake [16-18], then tumors dependent upon the ER
pathway for growth should display a decline in FDG up-
take as AI therapy lowers estradiol levels. These early
declines in FDG uptake corresponded to low post-
therapy proliferation (Ki-67), which predicts early re-
sponse to endocrine therapy [4]. For all 11 patients in
the AI group who showed an SUV decline of 20% or
greater, the Ki-67 at follow-up was ≤5%; for all three AI
patients who did not attain SUV reductions of 20% or
b ca
Figure 4 Associations between imaging and tissue measures. (a) Baseline FDG SUV and baseline Ki-67. (b) Percent change in FDG SUV and
percentage change in Ki-67. (c) Percent change in FDG SUV and follow-up Ki-67.
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the feasibility of serial FDG SUV as an early indicator of
response to endocrine therapy.
For trastuzumab, 6 of 12 patients showed substantial
decreases in FDG PET SUV, including 2 of 3 patients
with serial biopsy, but none of the three 2-week biop-
sies had Ki-67 expression ≤5%. Although numbers are
too small to draw conclusions, a less consistent pattern
of change is perhaps not surprising. Earlier studies have
suggested that T may mediate apoptotic pathways [7],
rather than resulting in an early change in proliferation.
In clinical practice and in most studies, T is given in
combination with chemotherapy. Data emerging from
recent neoadjuvant clinical trials suggest that HER2+
disease can be effectively targeted with additional
agents aimed at HER2 such as lapatinib [26] and pertu-
zumab [27]. Further study is needed before drawing
any conclusions about the efficacy of FDG PET as an
early indicator of response to trastuzumab or other
HER2-targeted therapies.
We did not see correspondence between change in
FDG uptake and change in Ki-67 with AI therapy. Al-
though post-therapy Ki-67 may be a better biomarker
than the change in Ki-67 (in the context of predicting
breast cancer recurrence) [4], other possible contribut-
ing factors are attributable to the preliminary nature of
our pilot study. Of the 17 baseline tissue samples avail-
able for pre-post comparisons, 11 were archival (8 AI 3
T), with intervening therapies including cytotoxic
chemotherapy, endocrine therapy, and HER2-targeted
therapy. Small sample size and heterogeneity of disease
characteristics and tissue biopsy sites may also con-
found our comparisons of imaging parameters to the
change in Ki-67.Another limitation of our study was the timing of im-
aging and biopsy. Our intentions were to assess the same
lesion by imaging and biopsy and to schedule FDG PET
scans before biopsy. However, clinical scheduling (diag-
nostic biopsy preceding PET scans) and feasibility con-
cerns (i.e., imaging of lesions near a high-contrast organ
or biopsy of an inaccessible tumor) had to be accommo-
dated. We did not find evidence that post-biopsy inflam-
mation strongly affected SUV. For three AI patients with
baseline FDG PET within 21 days after biopsy of the
index lesion (6, 13, 17 days), the percent changes in SUV
were −28%, −7%, and −3%. For the three AI patients
with post-therapy FDG PET within 21 days after biopsy
(3, 5, 7 days), the percent changes in SUV were −14%,
−47%, and −60%. If post-biopsy SUV were inflated, the
opposite trend (greater decrease when the baseline scan
occurred post-biopsy, lesser decrease when the post-
therapy scan occurred post-biopsy) would be expected.
Extension of run-in periods may be considered to avoid
having post-therapy scans within a healing period after
the baseline biopsy.
Our choice of a 20% threshold as attributable to ther-
apy was motivated by our hypothesis that short-term ex-
posure would produce a pharmacodynamic effect
detectable by FDG PET and beyond the limits of agree-
ment in test-retest studies. This is a different task than
the estimation of clinical response, for which alternative
measures such as PERCIST 1.0 have been suggested. Of
note, 8 of the 20 AI group patients with early response
by FDG PET SUV had decreases between 20% and 30%,
and 4 of those had absolute change in SUV of less than
1.2. Alternative measures of FDG uptake may provide
more robust evidence of a drug response [25]; however,
such analysis was beyond the scope of this pilot study.
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This pilot study supports the use of FDG PET to exam-
ine early response to endocrine therapy and exposed
challenges in collecting research biopsies in metastatic
lesions. Early response patterns to AI therapy seen by
imaging and biopsy were not apparent in response to T
therapy, supporting that the findings for AI therapy
were not due to technical issues in repeat imaging and/
or biopsy. A further study in patients with de novo early
stage disease, using paired serial imaging and tissue
sampling to investigate early response to preoperative
run-in targeted therapy, may determine whether im-
aging can replace tissue biomarkers. Our pilot data sup-
port the potential utility of molecular imaging with
FDG and other tracers as an in vivo assay to measure
pharmacodynamic effects of new anticancer drug ther-
apies and combinations.
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